MedTrace Logo

A Pilot Bioequivalence Study of Pomalidomide

NCT06058689 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-09-28

No results posted yet for this study

Summary

Pilot bioequivalence trial of two pomalidomide formulations consisting in 4 mg oral capsules.

Conditions

  • Bioequivalence Study

Interventions

DRUG

Pomalidomide 4 MG Oral Capsule

A single dose of 4 mg Pomalidomide per os, capsule, 4 mg, per period

Sponsors & Collaborators

  • Megalabs

    lead INDUSTRY

Principal Investigators

  • M. Gowtham, MD · Azidus Laboratories

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-15
Primary Completion
2024-11-15
Completion
2025-03-15

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06058689 on ClinicalTrials.gov